Aragen’s Developability Package for antibodies and other protein therapeutics allows you to make crucial data-driven decisions to select the final variant to advance as your clinical candidate. Molecules that are suitable for short-term Phase I studies at low doses can have hidden liabilities that may not present until later in clinical development when the cost of failure is high.
In addition to confirmation of sequence and post-translational modifications, Aragen’s Developability Package combines in silico methods and experimental data to identify, assess and mitigate potential problems including:
- Limited solubility
- Unwanted stress-induced post-translational modifications
- Aggregation formation during manufacturing, formulation and storage